<?xml version="1.0" encoding="UTF-8"?>
<p>Hepatitis B virus (HBV) has one of the highest morbidity rates and is sometimes referred to as the “second cancer.” There are 350 million patients with chronic HBV infection globally, 30–40% of which are chronic HBV patients. China is greatly affected by this epidemic, currently with 120 million chronic HBV infection cases and 3 million chronic HBV patients. It is estimated that the total direct and indirect loss due to chronic Hepatitis B (including Hepatocirrhosis and Hepatocellular Carcinoma) costs 90 billion Chinese RMB each year [
 <xref ref-type="bibr" rid="CR32">32</xref>]. Since all antiviral drugs for HBV and HCV are imported brand drugs, most people in developing countries, including China, cannot afford to use the antiviral drugs for their treatment.
</p>
